Flagship Pioneering is combining three portfolio companies—Etiome, Cellarity, and Empress Therapeutics—into a single new AI-aided drugmaker called Etcelera. The move aims to consolidate capabilities for predicting how new medicines will perform in humans, positioning the merged entity to compete more effectively in a crowded AI drug discovery arena. The reorganization signals continued pressure on standalone platforms to demonstrate measurable translational advantage, especially as investors look for speed-to-clinic and clearer evidence of human relevance. By unifying teams and technology stacks, Flagship is betting that scale and integration can improve prediction accuracy and reduce development friction. Details on leadership, pipeline status, and specific technical differentiation were not included in the snippet, but the merger itself indicates a strategic step toward a more coherent commercial and R&D identity. —